Activity of Meropenem-Vaborbactam against Carbapenem-Resistant Enterobacteriaceae in a Murine Model of Pyelonephritis.

Autor:	Weiss WJ; Pre-Clinical Services at UNT Health Science Center, Fort Worth, Texas, USA william.weiss@unthsc.edu., Pulse ME; Pre-Clinical Services at UNT Health Science Center, Fort Worth, Texas, USA., Nguyen P; Pre-Clinical Services at UNT Health Science Center, Fort Worth, Texas, USA., Peterson K; Pre-Clinical Services at UNT Health Science Center, Fort Worth, Texas, USA., Silva J; Pre-Clinical Services at UNT Health Science Center, Fort Worth, Texas, USA., Simecka JW; Pre-Clinical Services at UNT Health Science Center, Fort Worth, Texas, USA., Valtierra D; Pre-Clinical Services at UNT Health Science Center, Fort Worth, Texas, USA., Sabet M; The Medicines Company, San Diego, California, USA., Griffith DC; The Medicines Company, San Diego, California, USA.
Jazyk:	angličtina
Zdroj:	Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2017 Dec 21; Vol. 62 (1). Date of Electronic Publication: 2017 Dec 21 (Print Publication: 2018).
DOI:	10.1128/AAC.01439-17
Abstrakt:	The recently approved combination of meropenem and vaborbactam (Vabomere) is highly active against Gram-negative pathogens, especially Klebsiella pneumoniae carbapenemase (KPC)-producing, carbapenem-resistant Enterobacteriaceae We evaluated the efficacy of meropenem-vaborbactam against three clinically relevant isolates in a murine pyelonephritis model. The data indicate that the combination of meropenem and vaborbactam significantly increased bacterial killing compared to that with the untreated controls. These data suggest that this combination may have utility in the treatment of complicated urinary tract infections due to KPC-producing, carbapenem-resistant Enterobacteriaceae . (Copyright © 2017 American Society for Microbiology.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu